Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients

Maximilian T. Lobmeyer, Liewei M Wang, Issam Zineh, Stephen T Turner, John G. Gums, Arlene B. Chapman, Rhonda M. Cooper-Dehoff, Amber L. Beitelshees, Kent R Bailey, Eric Boerwinkle, Carl J. Pepine, Julie A. Johnson

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Objectives: The G-protein-coupled receptor kinases (GRKs) GRK2 and GRK5 are important regulators of β-adrenergic signaling. This study characterized single-nucleotide polymorphisms (SNPs) in the GRK2 gene (ADRBK1) and determined if these and a GRK5 Gln41Leu polymorphism affect the blood pressure (BP) response to atenolol or hydrochlorothiazide or adverse cardiovascular outcomes in hypertensives. METHODS: ADRBK1 regions were sequenced for 48 individuals. Putative functional SNPs were tested for mRNA expression differences in 96 lymphoblastoid cell line samples and 12 leukocyte samples from hypertensives. BP response to atenolol and hydrochlorothiazide by ADRBK1 SNPs and GRK5 Gln41Leu was tested in 418 patients from the Pharmacogenomic Evaluation of Antihypertensive Responses Study using linear regression. The influence of ADRBK1 SNPs and GRK5 Gln41Leu on death, myocardial infarction or stroke in treated hypertensives was evaluated in a case-control cohort (1 : 3) of the International Verapamil SR/Trandolapril Study GENEtic Substudy using logistic regression models. Results: A novel ADRBK1 promoter SNP was not associated with differential GRK2 expression. GRK5 Leu41 decreased the risk for adverse cardiovascular outcomes independent of treatment strategy (adjusted odds ratio 0.535, 95% confidence interval: 0.313-0.951, P=0.0222), but was not associated with BP response to antihypertensive medication. An ADRBK1 SNP (rs1894111 G>A) showed a signal for association with systolic and diastolic BP response to hydrochlorothiazide in Whites [diastolic BP: -11.29±3.74 (G/A) versus -4.26±4.79 mmHg (G/G), P=0.0034 and systolic BP: -18.37±14.90 (G/A), -8.11±7.55 mmHg (G/G), P=0.0191]. Conclusion: The GRK5 Leu41 allele protects from adverse cardiovascular outcomes in treated hypertensives.

Original languageEnglish (US)
Pages (from-to)42-49
Number of pages8
JournalPharmacogenetics and Genomics
Volume21
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Antihypertensive Agents
Blood Pressure
Single Nucleotide Polymorphism
Genes
Hydrochlorothiazide
trandolapril
Atenolol
Logistic Models
G-Protein-Coupled Receptor Kinases
Pharmacogenetics
Verapamil
Adrenergic Agents
Linear Models
Leukocytes
Stroke
Alleles
Odds Ratio
Myocardial Infarction
Confidence Intervals
Cell Line

Keywords

  • ADRBK1
  • atenolol
  • b-blocker
  • diuretic
  • GRK2
  • GRK5
  • hydrochlorothiazide
  • hypertension
  • polymorphism

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology
  • Molecular Medicine
  • Genetics(clinical)

Cite this

Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. / Lobmeyer, Maximilian T.; Wang, Liewei M; Zineh, Issam; Turner, Stephen T; Gums, John G.; Chapman, Arlene B.; Cooper-Dehoff, Rhonda M.; Beitelshees, Amber L.; Bailey, Kent R; Boerwinkle, Eric; Pepine, Carl J.; Johnson, Julie A.

In: Pharmacogenetics and Genomics, Vol. 21, No. 1, 01.2011, p. 42-49.

Research output: Contribution to journalArticle

Lobmeyer, MT, Wang, LM, Zineh, I, Turner, ST, Gums, JG, Chapman, AB, Cooper-Dehoff, RM, Beitelshees, AL, Bailey, KR, Boerwinkle, E, Pepine, CJ & Johnson, JA 2011, 'Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients', Pharmacogenetics and Genomics, vol. 21, no. 1, pp. 42-49. https://doi.org/10.1097/FPC.0b013e328341e911
Lobmeyer, Maximilian T. ; Wang, Liewei M ; Zineh, Issam ; Turner, Stephen T ; Gums, John G. ; Chapman, Arlene B. ; Cooper-Dehoff, Rhonda M. ; Beitelshees, Amber L. ; Bailey, Kent R ; Boerwinkle, Eric ; Pepine, Carl J. ; Johnson, Julie A. / Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. In: Pharmacogenetics and Genomics. 2011 ; Vol. 21, No. 1. pp. 42-49.
@article{9736331557b64939b9de9fdb51a6f42c,
title = "Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients",
abstract = "Objectives: The G-protein-coupled receptor kinases (GRKs) GRK2 and GRK5 are important regulators of β-adrenergic signaling. This study characterized single-nucleotide polymorphisms (SNPs) in the GRK2 gene (ADRBK1) and determined if these and a GRK5 Gln41Leu polymorphism affect the blood pressure (BP) response to atenolol or hydrochlorothiazide or adverse cardiovascular outcomes in hypertensives. METHODS: ADRBK1 regions were sequenced for 48 individuals. Putative functional SNPs were tested for mRNA expression differences in 96 lymphoblastoid cell line samples and 12 leukocyte samples from hypertensives. BP response to atenolol and hydrochlorothiazide by ADRBK1 SNPs and GRK5 Gln41Leu was tested in 418 patients from the Pharmacogenomic Evaluation of Antihypertensive Responses Study using linear regression. The influence of ADRBK1 SNPs and GRK5 Gln41Leu on death, myocardial infarction or stroke in treated hypertensives was evaluated in a case-control cohort (1 : 3) of the International Verapamil SR/Trandolapril Study GENEtic Substudy using logistic regression models. Results: A novel ADRBK1 promoter SNP was not associated with differential GRK2 expression. GRK5 Leu41 decreased the risk for adverse cardiovascular outcomes independent of treatment strategy (adjusted odds ratio 0.535, 95{\%} confidence interval: 0.313-0.951, P=0.0222), but was not associated with BP response to antihypertensive medication. An ADRBK1 SNP (rs1894111 G>A) showed a signal for association with systolic and diastolic BP response to hydrochlorothiazide in Whites [diastolic BP: -11.29±3.74 (G/A) versus -4.26±4.79 mmHg (G/G), P=0.0034 and systolic BP: -18.37±14.90 (G/A), -8.11±7.55 mmHg (G/G), P=0.0191]. Conclusion: The GRK5 Leu41 allele protects from adverse cardiovascular outcomes in treated hypertensives.",
keywords = "ADRBK1, atenolol, b-blocker, diuretic, GRK2, GRK5, hydrochlorothiazide, hypertension, polymorphism",
author = "Lobmeyer, {Maximilian T.} and Wang, {Liewei M} and Issam Zineh and Turner, {Stephen T} and Gums, {John G.} and Chapman, {Arlene B.} and Cooper-Dehoff, {Rhonda M.} and Beitelshees, {Amber L.} and Bailey, {Kent R} and Eric Boerwinkle and Pepine, {Carl J.} and Johnson, {Julie A.}",
year = "2011",
month = "1",
doi = "10.1097/FPC.0b013e328341e911",
language = "English (US)",
volume = "21",
pages = "42--49",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients

AU - Lobmeyer, Maximilian T.

AU - Wang, Liewei M

AU - Zineh, Issam

AU - Turner, Stephen T

AU - Gums, John G.

AU - Chapman, Arlene B.

AU - Cooper-Dehoff, Rhonda M.

AU - Beitelshees, Amber L.

AU - Bailey, Kent R

AU - Boerwinkle, Eric

AU - Pepine, Carl J.

AU - Johnson, Julie A.

PY - 2011/1

Y1 - 2011/1

N2 - Objectives: The G-protein-coupled receptor kinases (GRKs) GRK2 and GRK5 are important regulators of β-adrenergic signaling. This study characterized single-nucleotide polymorphisms (SNPs) in the GRK2 gene (ADRBK1) and determined if these and a GRK5 Gln41Leu polymorphism affect the blood pressure (BP) response to atenolol or hydrochlorothiazide or adverse cardiovascular outcomes in hypertensives. METHODS: ADRBK1 regions were sequenced for 48 individuals. Putative functional SNPs were tested for mRNA expression differences in 96 lymphoblastoid cell line samples and 12 leukocyte samples from hypertensives. BP response to atenolol and hydrochlorothiazide by ADRBK1 SNPs and GRK5 Gln41Leu was tested in 418 patients from the Pharmacogenomic Evaluation of Antihypertensive Responses Study using linear regression. The influence of ADRBK1 SNPs and GRK5 Gln41Leu on death, myocardial infarction or stroke in treated hypertensives was evaluated in a case-control cohort (1 : 3) of the International Verapamil SR/Trandolapril Study GENEtic Substudy using logistic regression models. Results: A novel ADRBK1 promoter SNP was not associated with differential GRK2 expression. GRK5 Leu41 decreased the risk for adverse cardiovascular outcomes independent of treatment strategy (adjusted odds ratio 0.535, 95% confidence interval: 0.313-0.951, P=0.0222), but was not associated with BP response to antihypertensive medication. An ADRBK1 SNP (rs1894111 G>A) showed a signal for association with systolic and diastolic BP response to hydrochlorothiazide in Whites [diastolic BP: -11.29±3.74 (G/A) versus -4.26±4.79 mmHg (G/G), P=0.0034 and systolic BP: -18.37±14.90 (G/A), -8.11±7.55 mmHg (G/G), P=0.0191]. Conclusion: The GRK5 Leu41 allele protects from adverse cardiovascular outcomes in treated hypertensives.

AB - Objectives: The G-protein-coupled receptor kinases (GRKs) GRK2 and GRK5 are important regulators of β-adrenergic signaling. This study characterized single-nucleotide polymorphisms (SNPs) in the GRK2 gene (ADRBK1) and determined if these and a GRK5 Gln41Leu polymorphism affect the blood pressure (BP) response to atenolol or hydrochlorothiazide or adverse cardiovascular outcomes in hypertensives. METHODS: ADRBK1 regions were sequenced for 48 individuals. Putative functional SNPs were tested for mRNA expression differences in 96 lymphoblastoid cell line samples and 12 leukocyte samples from hypertensives. BP response to atenolol and hydrochlorothiazide by ADRBK1 SNPs and GRK5 Gln41Leu was tested in 418 patients from the Pharmacogenomic Evaluation of Antihypertensive Responses Study using linear regression. The influence of ADRBK1 SNPs and GRK5 Gln41Leu on death, myocardial infarction or stroke in treated hypertensives was evaluated in a case-control cohort (1 : 3) of the International Verapamil SR/Trandolapril Study GENEtic Substudy using logistic regression models. Results: A novel ADRBK1 promoter SNP was not associated with differential GRK2 expression. GRK5 Leu41 decreased the risk for adverse cardiovascular outcomes independent of treatment strategy (adjusted odds ratio 0.535, 95% confidence interval: 0.313-0.951, P=0.0222), but was not associated with BP response to antihypertensive medication. An ADRBK1 SNP (rs1894111 G>A) showed a signal for association with systolic and diastolic BP response to hydrochlorothiazide in Whites [diastolic BP: -11.29±3.74 (G/A) versus -4.26±4.79 mmHg (G/G), P=0.0034 and systolic BP: -18.37±14.90 (G/A), -8.11±7.55 mmHg (G/G), P=0.0191]. Conclusion: The GRK5 Leu41 allele protects from adverse cardiovascular outcomes in treated hypertensives.

KW - ADRBK1

KW - atenolol

KW - b-blocker

KW - diuretic

KW - GRK2

KW - GRK5

KW - hydrochlorothiazide

KW - hypertension

KW - polymorphism

UR - http://www.scopus.com/inward/record.url?scp=78650680064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650680064&partnerID=8YFLogxK

U2 - 10.1097/FPC.0b013e328341e911

DO - 10.1097/FPC.0b013e328341e911

M3 - Article

C2 - 21127457

AN - SCOPUS:78650680064

VL - 21

SP - 42

EP - 49

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 1

ER -